| ID Source | ID |
|---|---|
| PubMed CID | 164652 |
| CHEMBL ID | 3187408 |
| CHEBI ID | 31582 |
| SCHEMBL ID | 207591 |
| MeSH ID | M0330371 |
| Synonym |
|---|
| bioflutin |
| etilefrine hcl |
| cardanat |
| efortil |
| etilefrin hydrochloride |
| 534-87-2 |
| (+-)-n-ethylnorphenylephrine hydrochloride |
| (+-)-ethylphenylephrine hydrochloride |
| zbi6q5fh3s , |
| etilefrine hydrochloride [jan] |
| unii-zbi6q5fh3s |
| dl-effortil hydrochloride |
| pulsamin |
| kertasin |
| eti-puren |
| 1-(3-hydroxyphenyl)-2-ethylaminoethanol hydrochloride |
| dl-1-(3-hydroxyphenyl)-1-hydroxy-2-ethylaminoethane hydrochloride |
| thomasin |
| einecs 213-398-8 |
| benzenemethanol, alpha-((ethylamino)methyl)-3-hydroxy-, hydrochloride |
| circupon |
| effortilvet |
| apocretin |
| alpha-((ethylamino)methyl)-m-hydroxybenzyl alcohol hydrochloride |
| benzyl alcohol, alpha-((ethylamino)methyl)-m-hydroxy-, hydrochloride |
| dl-etilefrin hydrochloride |
| tonus-forte |
| dl-1-(3-hydroxyphenyl-2-ethylaminoethanol hydrochloride |
| dl-ethylphenylephrine hydrochloride |
| phetasin |
| dl-n-ethylnorphenylephrine hydrochloride |
| NCGC00016496-01 |
| cas-534-87-2 |
| phetanol |
| updormin |
| ethyl adrianol |
| etilefrine hydrochloride |
| funasol |
| effontil |
| ethylephrine hydrochloride |
| D01573 |
| etilefrine hydrochloride (tn) |
| etilefrine hydrochloride (jp17) |
| 943-17-9 |
| FT-0668420 |
| E0381 |
| 2-ethylamino-1-(3-hydroxyphenyl)ethanol hydrochloride |
| HMS1571K15 |
| A844915 |
| 3-[2-(ethylamino)-1-hydroxy-ethyl]phenol hydrochloride |
| AKOS005267166 |
| 3-[2-(ethylamino)-1-hydroxyethyl]phenol hydrochloride |
| EN300-03375 |
| dtxsid1045322 , |
| dtxcid9025322 |
| tox21_110457 |
| FT-0603527 |
| (+/-)-ethylphenylephrine hydrochloride |
| SCHEMBL207591 |
| (rs)-2-ethylamino-1-(3-hydroxyphenyl)ethanol monohydrochloride |
| benzenemethanol, .alpha.-((ethylamino)methyl)-3-hydroxy-, hydrochloride (1:1) |
| (+/-)-n-ethylnorphenylephrine hydrochloride |
| ethylphenylephrine hydrochloride, dl- |
| etilefrin hydrochloride [mi] |
| etilefrine hydrochloride [mart.] |
| benzyl alcohol, .alpha.-((ethylamino)methyl)-m-hydroxy-, hydrochloride |
| etilefrine hydrochloride [ep monograph] |
| etilefrine hydrochloride [who-dd] |
| ethlyphenylephrine hydrochloride, dl |
| CCG-221017 |
| Q-201098 |
| CHEMBL3187408 |
| mfcd00060167 |
| sr-01000837506 |
| SR-01000837506-2 |
| CHEBI:31582 |
| etilefrin, hydrochloride |
| AS-13925 |
| etilefrine (hydrochloride) |
| 3-(2-(ethylamino)-1-hydroxyethyl)phenol hydrochloride |
| Q27295283 |
| D90499 |
| benzenemethanol, a-[(ethylamino)methyl]-3-hydroxy-, hydrochloride |
| 943-17-9 (hcl) |
| 3-[2-(ethylamino)-1-hydroxyethyl]phenol;hydrochloride |
| CS-0030673 |
| HY-A0144A |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (43.88) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||